Chimeric antigen receptor (CAR) T-cell-based immunotherapy, using IL1RAP as a tumor-associated antigen, has been proposed as a novel approach for the treatment of CML [76]. Here, IL1RAP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.